This study aimed to explore Australian women’s current knowledge, perspectives and attitudes about breast density (BD); and information needs to inform effective evidence-based communication strategies. The potential of being informed and notified of BD is found to be of interest and importance to Australian women [...]
The incidence of detected ductal carcinoma in situ (DCIS) continues to increase and now accounts for 14% of all breast cancer, and 20%–25% of screen-detected cases. Treatment trends of DCIS are important in order to inform the ongoing debate about possible overdiagnosis and overtreatment, but [...]
In a large breast cancer screening study, the benefits of prevalent digital breast tomosynthesis did not come at the expense of higher rates or more aggressive subsequent round screen-detected cancers.
In December 2017, the Australian National Cervical Screening Program (NCSP) changed from 2-yearly cervical cytology to 5-yearly primary human papillomavirus (HPV) testing, starting at age 25 and with an exit test when aged 70–74. Women showed limited awareness of these changes prior to their implementation. [...]
It is a rare study that successfully combines 3 different methods and data sets to address a research question. The study by Davies et al in this issue of JAMA Otolaryngology–Head & Neck Surgery examines the model of care offered to patients in Japan for papillary thyroid cancer. [...]
We agree with other analyses of the UK Age trial on the effect on breast cancer mortality of mammographic screening from age 40 years, including observations on the small absolute risk of dying from breast cancer for women aged between 40 and 50 years, and [...]
Ductal carcinoma in situ (DCIS) is an in-situ (pre-cancerous) breast malignancy whereby malignant cells are contained within the basement membrane of the breast ducts. Incidence has increased greatly since the introduction of organised breast screening, and DCIS now represents approximately 20% of screen-detected cancers, with [...]
Population mammography-screening programs aim to prevent women dying from breast cancer through earlier detection and treatment. Improvements in mammographic technology hold the promise of increasing the benefit of screening by increasing the detection of clinically important breast cancers. However, determining whether such theoretical benefits are [...]
The Australian National Cervical Screening Program (NCSP) introduced in 1991 has shown demonstrable success in reducing cervical cancer incidence and mortality in women aged 18 to 69 years screened with cytology every two years. Additionally, the implementation of a National Human Papillomavirus (HPV) Vaccination Program [...]
In December 2017, the Australian National Cervical Screening Program (NCSP) changed from cytology (Pap testing) to human papillomavirus (HPV) testing, increased the age of first invitation to screen, and extended the screening interval. These changes were known as the “Renewal”. When the changes were announced, [...]